Diagnostics
Researchers hope a blood test at the GP’s office will help identify early signs of Alzheimer’s in the future.
research. “The Alzheimer’s field has also grown a lot in the last 20 years due to increased attention and increased funding, but also because it’s blood and blood is so accessible. It raises interest from people who are maybe not Alzheimer’s researchers, but epidemiologists or cardiologist researchers … maybe their Alzheimer’s patients have had blood taken before. Maybe they have a study that’s been running for 30 years and we can now test that blood as well.” Just as significantly, the pivotal role of diagnostics in the Alzheimer’s ecosystem is now fully understood. “I think many people realise that to get to the end point of getting better treatments and better prevention, diagnostics are essential because they increase our understanding of the disease,” says Dr Vermunt. “For example, if you can predict what age people will get symptoms, you can get a very clear view of that timeline before people have symptoms.” Crucially, Dr Vermunt says predicting who will –
or won’t – get Alzheimer’s disease a decade or more down the line could also guide clinical trials. Identifying and recruiting patients for earlier inclusion in trials could ultimately accelerate the development of new drugs. “This is why I expect more progress [in treatments] in the coming years, because if we get more rationale or a better understanding of who to include and why, then your trials become better with better design, and you get more progress,” she explains.
In living memory
The significance of this point cannot be overstated, given the degree to which Alzheimer’s treatment research remains in the developmental phase. Identifying at-risk patients for inclusion in clinical studies could not only improve trial outcomes, but also save healthcare resources. This distinction has been made by a team at the Dementia Research Centre at the University College London’s Queen Square Institute of Neurology. In presenting the findings of their work on blood tests that measure
22
the amyloid beta protein, Professor Jonathan Schott predicted that biomarker tests could “radically” reduce the cost of clinical trials due to a reduction in the number of potential trial patients who would need more expensive PET scans. But Dr Vermunt sees a role for biomarker blood tests well after detection. Once disease-modifying treatments are available, Dr Vermunt says they could also be used to more efficiently track the patient journey. A blood test would be used to help make an initial diagnosis – either on its own or in combination with other diagnostic tools – and then it would be repeated at regular intervals to measure disease progression and to guide treatment. “In the future, we will want to start treatments not too early and not too late,” she says. “One of the powerful aspects of GFAP is that it might help predict when people are going to decline. When treatments are available, you would do a test to see how far away you are from developing dementia. Maybe five years before, you would then want to start preventive treatment and then you are going to want to also monitor the effects of that treatment.” Ultimately, it’s possible that blood tests could be combined with other technology to help detect and monitor cognitive decline. Alzheimer’s Research UK’s ambitious Early Detection of Neurodegenerative Diseases programme, for example, is using data collected from mobile apps and wearable devices to identify digital, behavioural signatures of Alzheimer’s in an effort to facilitate early detection and intervention.
Ethical and practical challenges of integrating Alzheimer’s testing into wider clinical environment exist – not least concerns about providing emotional support for patients who are told they may – many years later – develop a condition for which there is no effective treatment. Currently, as blood testing remains confined to the research environment, responsibility for patients with these “ticking time bomb” diagnoses must comply with trial ethics. For the moment, Dr Vermunt sees no reason for this to change and no benefit in pushing for blood testing for Alzheimer’s to be commercialised and made available in a community setting. “I think in terms of testing on individual level to predict disease in ten years … I don’t see a reason yet for aiming for that. You would only do that, I think, once there were good treatments available,” she says.
As the mysteries of Alzheimer’s slowly unravel,
it’s no coincidence that an increased understanding of the disease has evolved alongside diagnostic tools that are going back to the future in search of early signs of disease. But are effective treatments now finally on the horizon? “I always say that if I didn't think that it was possible, I wouldn't work on it,” Dr Vermunt says. “That’s the easiest answer.”
Practical Patient Care /
www.practical-patient-care.com
Pixel-Shot/
Shutterstock.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73
